Dec 20, 2021 8:30am EST BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients
Dec 15, 2021 8:30am EST European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis
Dec 06, 2021 7:00am EST SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
Dec 01, 2021 10:37am EST BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category
Nov 29, 2021 8:30am EST SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
Nov 23, 2021 8:30am EST SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection
Nov 10, 2021 7:34am EST SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 09, 2021 8:30am EST SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
